43 results on '"Secreto, Charla R"'
Search Results
2. B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells
3. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
4. Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients
5. Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance
6. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
7. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression
8. Differential transcriptomic profiling in ibrutinib‐naïve versus ibrutinib‐resistant Richter syndrome
9. B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells
10. Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia
11. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
12. Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma
13. Abstract 2209: Characterization of underlying genomic features among African ancestry populations diagnosed with chronic lymphocytic leukemia
14. Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter's Transformation
15. Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia
16. Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib
17. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression
18. Differential transcriptomic profiling in ibrutinib‐naïve versus ibrutinib‐resistant Richter syndrome.
19. Early Treatment of High-Risk Chronic Lymphocytic Leukemia With Alemtuzumab and Rituximab
20. A Role for TNF-α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction
21. Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance
22. Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy
23. Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance
24. Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Is Partially Mediated By Exposure to Constituents of the Leukemic Microenvironment
25. PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway
26. Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients
27. A novel mechanism of innate immune dysfunction in untreated Chronic Lymphocytic Leukemia.
28. Novel Mutations in NOTCH and Altered Wnt/beta-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia
29. Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase
30. Bone Marrow (BM) Hematopoietic Dysfunction in Chronic Lymphocytic Leukemia (CLL) - Association with Leukemic Burden and Reversibility with Therapeutic Responses.
31. PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)
32. Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia
33. Abstract B02: The Akt inhibitor MK-2206 in combination with rituximab and bendamustine demonstrates efficacy in relapsed/refractory chronic lymphocytic leukemia: Updated results from the NCCTG N1087 Alliance study
34. Identification of recurrent truncatedDDX3Xmutations in chronic lymphocytic leukaemia
35. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
36. Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia
37. Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG
38. Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).
39. Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.
40. Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.
41. ?-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance
42. A Role for TNF-a in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction
43. Novel Mutations in NOTCHand Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.